Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Not Yet Opened 09-02 16:00:00 EDT

5.80

+0.57

+10.90%

盘后5.81

+0.01+0.17%

19:56 EDT

High5.81	Low5.21	Vol993.29K
Open5.21	D1 Closing5.23	Amplitude11.47%
Mkt Cap181.48M	Tradable Cap106.68M	Total Shares31.29M
T/O5.51M	T/O Rate5.40%	Tradable Shares18.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":5.8,"timestamp":1788379200000,"preClose":5.23,"halted":0,"volume":993293,"hourTrading":{"tag":"盘后","latestPrice":5.81,"preClose":5.8,"latestTime":"19:56 EDT","volume":9070,"amount":52397.114,"timestamp":1788393406060,"change":0.01,"changeRate":0.001724,"amplitude":0.041379},"delay":0,"changeRate":0.10898661567877617,"floatShares":18393300,"shares":31289969,"eps":-4.13,"marketStatus":"Not Yet Opened","change":0.57,"latestTime":"09-02 16:00:00 EDT","open":5.21,"high":5.81,"low":5.21,"amount":5510568.7549661,"amplitude":0.114723,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788422400000},"marketStatusCode":0,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":5.23,"preHourTrading":{"tag":"盘前","latestPrice":5.21,"preClose":5.23,"latestTime":"08:13 EDT","volume":216,"amount":1115.4340008,"timestamp":1788351182046,"change":-0.02,"changeRate":-0.003824,"amplitude":0.053537},"postHourTrading":{"tag":"盘后","latestPrice":5.81,"preClose":5.8,"latestTime":"19:56 EDT","volume":9070,"amount":52397.114,"timestamp":1788393406060,"change":0.01,"changeRate":0.001724,"amplitude":0.041379},"volumeRatio":1.663924,"impliedVol":3.6505,"impliedVolPercentile":0.9762},"requestUrl":"/m/hq/s/LENZ/wiki","defaultTab":"wiki","newsList":[{"id":"2664257448","title":"Cutia Therapeutics' Marketing Application for Botox Product Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2664257448","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664257448?lang=en_us&edition=fundamental","pubTime":"2026-09-03 12:03","pubTimestamp":1788408198,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics (HKG:2487) said its biologics license application for CU-20101, or botulinum toxin type A, has been accepted by China's medical products regulator, according to a Thursday filing.The indication is for improving moderate-to-severe glabellar lines, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02487","BK4539","BK4139","BK1161","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664847851","title":"IMPACT Therapeutics CEO Boosts Stake in Hong Kong–Listed Biopharma Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2664847851","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664847851?lang=en_us&edition=fundamental","pubTime":"2026-09-03 08:08","pubTimestamp":1788394096,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. Class H ( ($HK:7630) ) just unveiled an update. IMPACT Therapeutics’ chief executive officer and executive director, Dr. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/impact-therapeutics-ceo-boosts-stake-in-hong-kong-listed-biopharma-group?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/impact-therapeutics-ceo-boosts-stake-in-hong-kong-listed-biopharma-group?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664214842","title":"Alterity Therapeutics to Spotlight MSA Program at Cantor Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664214842","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664214842?lang=en_us&edition=fundamental","pubTime":"2026-09-03 07:47","pubTimestamp":1788392845,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics, a clinical-stage biotechnology company developing disease-modify...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-to-spotlight-msa-program-at-cantor-global-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-to-spotlight-msa-program-at-cantor-global-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","RSPH","FWD","BK4539","DARP","BK4137","FHLC","XBI","BBP","HCSG","XLV","JDOC","SYNB","LABU","BK4585","LENZ","IEIH","AGNG","IBB","LU0029874061.USD","XT","BK4007","BK4588","BBC","LNGR","BK4139","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664841403","title":"Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664841403","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664841403?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:00","pubTimestamp":1788382800,"startTime":"0","endTime":"0","summary":"NEW YORK and WALTHAM, Mass., Sept.  02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355541/0/en/dianthus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","LENZ","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664841409","title":"Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664841409","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664841409?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:30","pubTimestamp":1788381000,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Sept.  02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for peopl","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355531/0/en/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","LCLG","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664784985","title":"Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664784985","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664784985?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:01","pubTimestamp":1788379260,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Sept.  02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355479/0/en/spero-therapeutics-to-present-at-h-c-wainwright-28th-annual-global-investment-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664803846","title":"Needham Downgrades TScan Therapeutics to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2664803846","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664803846?lang=en_us&edition=fundamental","pubTime":"2026-09-03 02:48","pubTimestamp":1788374901,"startTime":"0","endTime":"0","summary":"Price: 0.36, Change: -0.31, Percent Change: -45.97","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664455718","title":"TScan Therapeutics downgraded to Hold from Buy at Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2664455718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664455718?lang=en_us&edition=fundamental","pubTime":"2026-09-03 01:50","pubTimestamp":1788371415,"startTime":"0","endTime":"0","summary":"Needham downgraded TScan Therapeutics (TCRX) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tscan-therapeutics-downgraded-to-hold-from-buy-at-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tscan-therapeutics-downgraded-to-hold-from-buy-at-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664437478","title":"Halozyme Therapeutics Price Target Maintained with a $115.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2664437478","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664437478?lang=en_us&edition=fundamental","pubTime":"2026-09-03 01:33","pubTimestamp":1788370380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HALO/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664810811","title":"Wedbush Downgrades TScan Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $5","url":"https://stock-news.laohu8.com/highlight/detail?id=2664810811","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664810811?lang=en_us&edition=fundamental","pubTime":"2026-09-02 22:41","pubTimestamp":1788360086,"startTime":"0","endTime":"0","summary":"Price: 0.43, Change: -0.24, Percent Change: -35.51","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811229","title":"Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811229","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811229?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:30","pubTimestamp":1788352200,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Sept.  02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (Allo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355132/0/en/allogene-therapeutics-announces-retirement-of-chief-financial-officer-geoffrey-parker.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819046","title":"Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819046","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664819046?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:00","pubTimestamp":1788350400,"startTime":"0","endTime":"0","summary":"WATERTOWN, Mass., Sept.  02, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355075/0/en/acrivon-therapeutics-to-present-at-the-2026-cantor-global-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","XBI","LU0029874061.USD","LENZ","BK4588","LU0128526141.USD","XLV","LABU","BK4539","BK4007","BK4137","BK4139","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819124","title":"TScan Therapeutics Restructures to Focus on Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819124","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664819124?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:59","pubTimestamp":1788350350,"startTime":"0","endTime":"0","summary":"The latest update is out from TScan Therapeutics ( ($TCRX) ). On September 2, 2026, TScan Therapeutics announced a strategic reorganization that sh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tscan-therapeutics-restructures-to-focus-on-solid-tumors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tscan-therapeutics-restructures-to-focus-on-solid-tumors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","TCRX","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664815050","title":"TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2664815050","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664815050?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:00","pubTimestamp":1788346800,"startTime":"0","endTime":"0","summary":"Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated data from Cohort C of the Phase 1 ALLOHA","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3354974/0/en/tscan-therapeutics-announces-strategic-reorganization-to-focus-on-in-vivo-cell-therapy-for-solid-tumors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4539","LENZ","EES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664159448","title":"Goldman Sachs Sticks to Their Hold Rating for Ocumension Therapeutics (1477)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664159448","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664159448?lang=en_us&edition=fundamental","pubTime":"2026-09-02 18:56","pubTimestamp":1788346587,"startTime":"0","endTime":"0","summary":"In a report released today, from Goldman Sachs maintained a Hold rating on Ocumension Therapeutics, with a price target of HK$7.92. The word on The...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/goldman-sachs-sticks-to-their-hold-rating-for-ocumension-therapeutics-1477-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/goldman-sachs-sticks-to-their-hold-rating-for-ocumension-therapeutics-1477-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664997828","title":"Aptabio Therapeutics Plans Seoul NDR to Deepen R&D Dialogue with Institutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2664997828","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664997828?lang=en_us&edition=fundamental","pubTime":"2026-09-02 14:21","pubTimestamp":1788330080,"startTime":"0","endTime":"0","summary":"Aptabio Therapeutics, Inc. ( ($KR:293780) ) has provided an update. Aptabio Therapeutics, Inc., a biotechnology company focused on research and dev...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aptabio-therapeutics-plans-seoul-ndr-to-deepen-rd-dialogue-with-institutions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aptabio-therapeutics-plans-seoul-ndr-to-deepen-rd-dialogue-with-institutions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4585","FHLC","FWD","BK4588","IEIH","BK4007","JDOC","LNGR","XT","BK4139","AGNG","DARP","RSPH","IBB","BK4539","SYNB","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664996128","title":"Retail Employees Super Fund Exits Substantial Holding in PYC Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2664996128","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664996128?lang=en_us&edition=fundamental","pubTime":"2026-09-02 14:15","pubTimestamp":1788329749,"startTime":"0","endTime":"0","summary":"An announcement from PYC Therapeutics Limited ( ($AU:PYC) ) is now available. Retail Employees Superannuation Pty Ltd, acting as trustee of the Ret...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/retail-employees-super-fund-exits-substantial-holding-in-pyc-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/retail-employees-super-fund-exits-substantial-holding-in-pyc-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664999896","title":"Prescient Therapeutics Hits Dose Optimization Review Milestone in Cancer Drug Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2664999896","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664999896?lang=en_us&edition=fundamental","pubTime":"2026-09-02 13:38","pubTimestamp":1788327489,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  reached the pre-specified enrollment threshold for its first planned dose optimization committee review in a phase 2a study of its PTX-100 drug candidate in relapsed or refractory cutaneous T-cell lymphoma, according to a Wednesday filing with the Australian bourse.The company said 10 evaluable patients, or those who have completed four cycles of treatment, are now enrolled in each of the study's two dosing arms for 20 evaluable patients in total.The first dose optimization committee review remains on track for December, and enrollment in the study continues globally toward a full target of 40 evaluable patients.Cutaneous T-cell lymphoma is a type of immune system cancer where abnormal white blood cells migrate to and attack the skin.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PTX.AU","BK4007","BK7067","BK4539","LENZ","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664508978","title":"Kazia Therapeutics is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2664508978","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664508978?lang=en_us&edition=fundamental","pubTime":"2026-09-01 23:06","pubTimestamp":1788275160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KZIA/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664285768","title":"BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2664285768","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664285768?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:26","pubTimestamp":1788272819,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical ( ($BMRN) ) just unveiled an announcement. BioMarin Pharmaceutical Inc. has completed the acquisition of Dutch biotech comp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biomarin-completes-acquisition-of-dutch-biotech-alesta-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biomarin-completes-acquisition-of-dutch-biotech-alesta-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4588","XBIX","BK4581","LENZ","XBI","BK4585","BK4539","NVIB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":0.2134},{"period":"1month","weight":0.1612},{"period":"3month","weight":-0.1944},{"period":"6month","weight":-0.503},{"period":"1year","weight":-0.8522},{"period":"ytd","weight":-0.6375}],"compareEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":0.0099},{"period":"3month","weight":0.0107},{"period":"6month","weight":0.138},{"period":"1year","weight":0.1951},{"period":"ytd","weight":0.1221}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.134259},{"month":6,"riseRate":0.6,"avgChangeRate":-0.009929},{"month":7,"riseRate":0.5,"avgChangeRate":0.033083},{"month":8,"riseRate":0.333333,"avgChangeRate":0.01095},{"month":9,"riseRate":0.666667,"avgChangeRate":0.04127},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}